The Milton and Carroll Petrie Department of Urology is part of the Mount Sinai Health System and has been a leader in clinical practice, research, and education since 1852, with the establishment of The Mount Sinai Hospital. Today, depth of knowledge, breadth of experience, and compassion for patients continue to characterize our highly respected team of board certified and fellowship trained physicians whom are also faculty of the Icahn School of Medicine at Mount Sinai. Our dedicated team of urologists specialize in treatment of urologic cancer, kidney stones, sexual dysfunction, and endourological conditions. Our surgeons and scientists have pioneered the adoption of novel diagnostic techniques and minimally invasive treatments for prostate, kidney, bladder, and renal cell cancers though our industry-leading international symposia.
As globally recognized experts, we provide in depth training on cutting-edge medical advances and are among the most renowned in the world performing robotic surgery making our robotics program among the most robust in the country. Our Kidney Stone Center was the first of its kind in New York, focusing on both treatment and prevention. Genomic testing and advanced imaging are routine for patients with prostate cancer in order to provide them with the most personalized and precise treatment protocols. Our specialized men’s, women’s, children’s, reconstructive, and gender affirming programs ensure that we can meet the needs of every patient with exceptional quality of service.
The Department of Urology at The Mount Sinai Hospital is ranked No. 11 in the nation by U.S. News & World Report® for 2024-25.
The Milton and Carroll Petrie Department of Urology is part of the Mount Sinai Health System and has been a leader in clinical practice, research, and education since 1852, with the establishment of The Mount Sinai Hospital. Today, depth of knowledge, breadth of experience, and compassion for patients continue to characterize our highly respected team of board certified and fellowship trained physicians whom are also faculty of the Icahn School of Medicine at Mount Sinai. Our dedicated team of urologists specialize in treatment of urologic cancer, kidney stones, sexual dysfunction, and endourological conditions. Our surgeons and scientists have pioneered the adoption of novel diagnostic techniques and minimally invasive treatments for prostate, kidney, bladder, and renal cell cancers though our industry-leading international symposia.
As globally recognized experts, we provide in depth training on cutting-edge medical advances and are among the most renowned in the world performing robotic surgery making our robotics program among the most robust in the country. Our Kidney Stone Center was the first of its kind in New York, focusing on both treatment and prevention. Genomic testing and advanced imaging are routine for patients with prostate cancer in order to provide them with the most personalized and precise treatment protocols. Our specialized men’s, women’s, children’s, reconstructive, and gender affirming programs ensure that we can meet the needs of every patient with exceptional quality of service.
The Department of Urology at The Mount Sinai Hospital is ranked No. 11 in the nation by U.S. News & World Report® for 2024-25.
Latest Content |view more
Significant Advances in Cancer Treatment and Research for the Department of Urology
Significant advances in patient care and research by the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai were recognized as the Department recorded a number of significant milestones in 2023 ...
An Important Milestone: Marking the 500th Robotic Cystectomy Surgery in the Bladder Cancer Program
A team at the Department of Urology recently performed the 500throbotic cystectomy in Mount Sinai’s Bladder Cancer Program, a significant milestone that underscores innovations in patient care, research, and clinical excellence that make ...
Rethinking the Role of Lymph Nodes in Prostate Cancer: A study from Mount Sinai
In this study, Ash Tewari, MD and additional authors at Mount Sinai suggest re-evaluating the common practice of removing lymph nodes during prostate cancer surgery, as it can be risky and may not provide therapeutic benefits.
A recent study conducted at Mount Sinai Hospital has demonstrated the safety and effectiveness of the Menon Precision Prostatectomy (MPP), a surgical technique for treating prostate cancer while preserving urinary and sexual functions.
One of the biggest challenges in managing aggressive and locally advanced prostate cancer is how best to balance the competing goals of achieving cancer control with maintaining continence and sexual function among patients.
The Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai has long been a leader in clinical practice, education, and research, where we perform complex procedures using robotics, laparoscopy, and ...
Landmark Symposium on Urologic Oncology Showcases Groundbreaking Research and Clinical Practices
The Icahn School of Medicine at Mount Sinai recently took center stage in the global medical community by hosting the Fifth International Prostate Cancer Symposium and World Congress of Urologic Oncology.
New Algorithm Guides Decision-Making for Single-Port and Multiport Robotic Nephrectomy
A patient-focused, clinical decision-making algorithm to determine the optimal approach between single-port and multiport robotic surgery will help guide surgeons in selecting the appropriate treatment for each patient.
Ureteroscopies Without Wires and Stents Could Be the Field’s Next Gold Standard
Mantu Gupta, MD, is leading the movement to set a new gold standard for the field through the use of flexible ureteroscopes untethered to wires, sheaths, and stents—and the severe discomfort they can cause patients.
In this video, Dr. Badani, Director of the Kidney Cancer Center at the Mount Sinai Health System, and Professor of Urology at the Icahn School of Medicine at Mount Sinai, demonstrates this standardized approach that has evolved over his large experience.
Continuing Innovation Leads to Advances in Treatments for BPH Patients
While Aquablation® continues to gain traction as a highly effective therapy for benign prostatic hyperplasia (BPH), the Optilume® BPH Catheter System, another innovative treatment option using drug-coated balloon technology moved closer ...
A Mount Sinai Team of Urologic Researchers Advances a Unique Model of Bladder Cancer Resistance
An inactivated form of tuberculosis bacterium known as Bacillus Calmette-Guerin (BCG) has been the only first-line therapy for urologists treating non-muscle invasive bladder cancer.
In its second year, the Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit is demonstrating its ability to change the outcome of prostate cancer for the communities Mount Sinai serves, even as the Department continues to ...
The Urology Residency Program at Mount Sinai: A Focus on Continuous Improvement
A key focus for leaders of the Department of Urology Training Program, and one reason for its success, is a commitment to continuous improvement, and a critical element of that has been keeping lines of communication open.
Probing “DNA Damage Repair Genes” to Change Outcomes for Castration-Resistant Prostate Cancer
Prostate cancer is the second leading cause of cancer death among men in the United States. For patients whose disease do not respond well to treatment, a Mount Sinai researcher is attempting to change that reality with his work on BRCA2 ...
Register Now for the Mount Sinai Urology Symposium Dec 8-10 in NYC
Join us for the Fifth International Prostate Cancer Symposium and World Congress of Urologic Oncology presented by Mount Sinai.
New Urologic Oncology Fellowship Program Aims for Research, Surgical Excellence
The new urologic oncology program launched by the Department of Urology, fully accredited by the Society of Urologic Oncology, has an equal focus on developing clinical and research skills.
While many bladder cancer patients have benefited from neoadjuvants, their application in prostate and kidney cancers is currently confined to clinical trials.
Transgender Surgery at the Department of Urology at Mount Sinai with Miroslav Djordjevic MD, PhD
Dr. Djordjevic of the Mount Sinai Department of Urology's transgender surgery program discusses a variety of feminizing genital surgery options for vaginoplasty and techniques for masculinizing genital surgery.
Transgender Surgery at the Department of Urology at Mount Sinai with Rajveer Purohit, MD, MPH
Dr. Purohit of the Mount Sinai Department of Urology's transgender surgery program shares feminizing genital surgery options for vaginoplasty, metoidioplasty and phalloplasty.
Case Study: Multidisciplinary Care for Renal Replacement Patient
A neonate with severe kidney injury and likely urinary blockage causing severe hydronephrosis received successful treatment at Mount Sinai for his rare birth defect.
Mount Sinai has developed a protocol that eliminates opioids from postoperative pain management with exceptional results.
Harnessing Immunotherapy to Achieve Improved Outcomes for Patients With Prostate Cancer
Although there is considerable interest in using immunotherapy to combat and control prostate cancer, there has been little progress made in harnessing the potential of this approach.
Two Physician-Researchers Making Unique Contributions to Urology Innovation
Two physician-researchers in the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai have been recognized for making unique contributions to urology research...
Prostate Cancer Program: Two Pioneering Studies
For more than a decade, Ash Tewari, MBBS, MCh, FRCS (Hon.), has been a leader in advancing the safety and precision of robot-assisted radical prostatectomies.
By continuing to perfect the miniaturization of percutaneous nephrolithotomy (PCNL), surgeons at the Mount Sinai Department of Urology are significantly improving outcomes for patients with larger kidney stones.
Kidney Research Pipeline to Enhance Precision in Surgical Intervention Decisions
Advances in imaging, biomarkers, and genetic testing continue to benefit patients who present with prostate and bladder cancers.
Advancing the Field of Gender Affirming Surgery Through Innovative Approaches
Mount Sinai has established itself as a leader in gender affirming surgery and reconstruction of genitalia, thanks in part to the pioneering work of Miroslav Djordjevic, MD, PhD, a leading authority on surgery for transgender individuals.
Urology Training Program at Mount Sinai Offers Residents Unique Opportunities
The Urology Residency Program of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai provides residents the opportunity to train in all aspects of the medical and surgical evaluation and treatment ...
Mount Sinai’s Department of Urology continues to make strides in training a new generation in the necessary clinical, surgical, and decision-making skills to deliver outstanding care to patients in an area undergoing rapid change.
Organoids Enable Pathophysiology, Treatment Studies of Rare Renal Cell Carcinomas
For years, rare renal cell carcinomas (RCCs), such as papillary RCC, have been understudied because their incidences are too low to support clinical trials.
Better Diagnosis Holds the Key to Improved Outcomes for BPH Patients
As the family of technologies for treating benign prostatic hyperplasia (BPH) continues to grow, the key to successful outcomes for male patients may well rest on a rather simple tenet: better diagnostic acumen.
An innovative effort by the Milton and Carroll Petrie Department of Urology and Ash Tewari, MBBS, MCh, FRCS (Hon.), Professor and System Chair, to improve early detection of prostate cancer among at-risk populations in New York City...
Message from the Chair: Milestones are meant to be celebrated and surpassed. For the year 2022, our milestones are a reflection of our collective efforts to save lives—through innovative patient care and groundbreaking research and scholastic activities.
Immunotherapy After Bladder Cancer Surgery Shows Excellent Cancer-free Survival Rates
Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle...
Mount Sinai Pediatric Stone Clinic Diagnoses, Treats, and Prevents Kidney Stones in Children
The Mount Sinai Pediatric Stone Clinic is a comprehensive, interdisciplinary program focused on the diagnosis, management, and prevention of kidney stones in children.
The COVID-19 pandemic forced us to find the strength we never knew we had. It has revealed our anti-fragile mindset in our mission to provide unparalleled, comprehensive, and innovative patient care.
Ash Tewari, MD presents insights into the role of genomics on prostate cancer
A Conversation With Deepak Chopra
Ash Tewari, MBBS, MCh, FRCS (Hon.) discusses wellness and well-being with Deepak Chopra, MD
Urology Training Program at Mount Sinai Prepares Residents for Success
Learn more about the Urology Residency Program of the Department of Urology at the Icahn School of Medicine at Mount Sinai
Ultra-Mini PCNL: A New Approach to Treating Kidney Stones
At Mount Sinai, Mantu Gupta, MD, a pioneer in PCNL procedures, is helping to popularize a new approach to treating kidney stones that is not only cost efficient but also safe and effective: ultra-mini PCNL
Offering Patients Innovative Options for Penile Enhancement
For years, Robert Valenzuela, MD, cautioned patients that they might experience shortening of their penis following a penile prosthesis implantation (PPI) for erectile dysfunction. Today, he advises them that they might have a longer one
Developing a Single Port Donor Nephrectomy Program to Provide Benefits for Patients
Michael Palese, MD continues to advance the standard of care for patients undergoing robotic multiport living donor nephrectomy (LDN)
Ketan Badani, MD believes a significant percentage of kidney and adrenal tumors can be done using a robot-assisted retroperitoneal approach
Mount Sinai and the NYC launch of a new Mobile Prostate Cancer Screening Unit aiding the Black Community.
Mount Sinai is developing a fully personalized therapeutic vaccine directed toward mutation-derived tumor antigens—in combination with CDX-301, a potent hematopoietic cytokine.
Aquablation is Proving to Be an Innovative and Successful Approach in BPH Procedures
Steven A. Kaplan, MD, using Aquablation® therapy, he is able to treat patients presenting with similar size prostates in approximately eight minutes
Mount Sinai Begins Offering High-Intensity Focused Ultrasound (HIFU) for Localized Prostate Tumors
Mount Sinai has begun offering patients high-intensity focused ultrasound (HIFU) for targeted ablation of localized prostate tumors
Dr. Tewari’s focus on precision medicine, scientific innovation, and offering patients more options exemplifies Mount Sinai’s leadership in translating insights from research to clinical practice
Precision Prostatectomy Approach Helps Preserve Erectile Function Among Patients
Mani Menon, MD discusses advances in robotic prostatectomy surgery
Robotic Approach to Testicular Cancer Treatment Potentially Safe, Effective, Reproducible
Department Receives $4 Million Gift to Support Prostate Health
The donation from Lizzie and Jonathan Tisch will support prostate health and the Department of Urology and continues their generous history of philanthropic giving at Mount Sinai
Mount Sinai Holds Prostate Cancer Research Stay at Home Gala to Showcase Research Priorities
The event highlighted the Department’s research in prostate cancer, beginning with the impact of the COVID-19 pandemic
A review of data from around the world by Mount Sinai researchers confirms that men face a greater risk of infection and mortality from COVID-19 and that routine screening should be conducted for the disease among prostate cancer patients
Research Initiatives Include Two New Grants from the National Institutes of Health
The Department of Urology at the Icahn School of Medicine at Mount Sinai is building on its legacy of innovation in research and therapeutic treatments with two new National Institutes of Health grants focused on the mechanisms that drive ...
A More Comprehensive, Patient-Centered Approach to Staghorn Calculi
Mount Sinai’s approach to care is focused on understanding the root causes of the disease by pioneering new treatments and developing customized postoperative regimens that reduce the risk of redevelopment, resulting in improved outcomes
Robotic Single Port Donor Nephrectomy
The team from Mount Sinai believes the new Single Port platform from Intuitive Surgical is uniquely suited for the LDN procedure
Rezum Therapy for Patients with Large Prostate Glands
Michael A. Palese, MD, Professor of Urology at the Icahn School of Medicine at Mount Sinai and Director of Minimally Invasive Surgery, along with his team, evaluated the use of Rezum technology for prostates greater than 80 grams
A review of COVID-19 literature could lead to effective simultaneous treatment of both diseases
Peter Wiklund, MD, PhD has become one of the first surgeons in the world to use a single-port robot to perform radical cystectomies with a urinary diversion